Next Article in Journal
Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors
Previous Article in Journal
Functional and Phylogenetic Diversity of BSH and PVA Enzymes
Article

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

1
Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
2
Institute for Transfusion Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
3
Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany
4
Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany
5
Institute for Clinical Chemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
6
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
7
German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 50931 Cologne, Germany
8
Nierenzentrum Bonn, Godesberger Allee 26, 53175 Bonn, Germany
9
Department II of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
10
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, CECAD, University of Cologne, 50931 Cologne, Germany
11
Institute for Experimental Dentistry and Oral Musculoskeletal Biology, and Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Sofia Costa-de-Oliveira
Microorganisms 2021, 9(4), 733; https://doi.org/10.3390/microorganisms9040733
Received: 7 March 2021 / Revised: 23 March 2021 / Accepted: 26 March 2021 / Published: 31 March 2021
(This article belongs to the Section Medical Microbiology)
Background: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. Methods: Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys® anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. Results: Overall, the IDK® anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. Conclusions: The novel IDK® anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic. View Full-Text
Keywords: pandemic; humoral response; neutralization; titer; protection; non-responder; coronavirus; antibody; COVID-19; sensitivity pandemic; humoral response; neutralization; titer; protection; non-responder; coronavirus; antibody; COVID-19; sensitivity
Show Figures

Figure 1

MDPI and ACS Style

Eberhardt, K.A.; Dewald, F.; Heger, E.; Gieselmann, L.; Vanshylla, K.; Wirtz, M.; Kleipass, F.; Johannis, W.; Schommers, P.; Gruell, H.; Brensing, K.A.; Müller, R.-U.; Augustin, M.; Lehmann, C.; Koch, M.; Klein, F.; Di Cristanziano, V. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms 2021, 9, 733. https://doi.org/10.3390/microorganisms9040733

AMA Style

Eberhardt KA, Dewald F, Heger E, Gieselmann L, Vanshylla K, Wirtz M, Kleipass F, Johannis W, Schommers P, Gruell H, Brensing KA, Müller R-U, Augustin M, Lehmann C, Koch M, Klein F, Di Cristanziano V. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms. 2021; 9(4):733. https://doi.org/10.3390/microorganisms9040733

Chicago/Turabian Style

Eberhardt, Kirsten A., Felix Dewald, Eva Heger, Lutz Gieselmann, Kanika Vanshylla, Maike Wirtz, Franziska Kleipass, Wibke Johannis, Philipp Schommers, Henning Gruell, Karl A. Brensing, Roman-Ulrich Müller, Max Augustin, Clara Lehmann, Manuel Koch, Florian Klein, and Veronica Di Cristanziano. 2021. "Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG" Microorganisms 9, no. 4: 733. https://doi.org/10.3390/microorganisms9040733

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop